Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Author Correction: Real-world...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Show other versions (1)
Bibliographic Details
Published in:npj Breast Cancer
Main Authors: Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Format: Article
Language:English
Published: Nature Portfolio 2023-10-01
Online Access:https://doi.org/10.1038/s41523-023-00596-1
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1038/s41523-023-00596-1

Similar Items

  • Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    by: Alessandra Fabi, et al.
    Published: (2023-09-01)
  • Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    by: Alessandra Fabi, et al.
    Published: (2024-02-01)
  • Remarks on an Identity of Anastase and Díaz-Barrero
    by: Horst Alzer, et al.
    Published: (2025-06-01)
  • Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma
    by: Ilaria Trestini, et al.
    Published: (2021-09-01)
  • Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
    by: Elisa Giommoni, et al.
    Published: (2021-05-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs